Watch MTNB. Know when insiders buy.
One email the day a filing lands. Free.
MTNB
Matinas BioPharma Holdings, Inc.
1.60
−0.10 −5.88%
USD · close Oct 21
A free account adds a watchlist, alerts when insiders, Congress or short sellers move on your tickers, and a morning brief. Sign up
Work order
0
FLAG · shorts 0
Insiders, 90 days
0
no open-market filings in 90 days
Congress, 90 days
0 / 0
no disclosures naming it
Big money
0 / 15
none of the tracked funds disclose it
Calls on record
0
nobody we score has called it yet
MKT CAP $23.5MP/E —DIV YIELD —FCF YIELD —REV TTM —NET INCOME −$6.7MNET CASH —52W 0.16 – 4.47SEC XBRL · TTM TO Invalid Date
Financials
By quarter
| Period | Revenue | YoY | Gross margin | Operating income | Net income | YoY | EPS | Op. cash flow | Capex | Free cash flow | Filed |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Q2 2026 · Jun 30 | — | — | — | −$1.6M | −$1.3M | — | -0.21 | −$1.8M | — | — | Aug 13 |
| Q1 2026 · Mar 31 | — | — | — | −$1.9M | −$1.9M | — | -0.30 | −$1.6M | — | — | May 8 |
| Q4 2025 · Dec 31derived | — | — | — | −$1.6M | −$1.9M | — | -0.26 | −$1.5M | — | — | Mar 31 |
| Q3 2025 · Sep 30 | — | — | — | −$1.6M | −$1.5M | — | -0.40 | −$1.5M | — | — | Nov 10 |
| Q2 2025 · Jun 30 | — | — | — | −$1.8M | −$5.2M | — | -1.03 | −$2M | — | — | Aug 13 |
| Q1 2025 · Mar 31 | — | — | — | −$1.9M | −$1.7M | — | -0.33 | −$2M | — | — | May 8 |
| Q4 2024 · Dec 31derived | — | — | — | −$8.5M | −$8.4M | — | -1.68 | −$3.5M | — | — | Mar 31 |
| Q3 2024 · Sep 30 | — | — | — | −$4.4M | −$4.3M | — | -0.85 | −$3.5M | — | — | Nov 10 |
| Q2 2024 · Jun 30 | — | — | — | −$5.8M | −$5.7M | — | -1.15 | −$3.1M | — | — | Aug 14 |
| Q1 2024 · Mar 31 | — | — | — | −$5.9M | −$5.8M | — | -1.34 | −$5.8M | — | — | May 15 |
| Q4 2023 · Dec 31derived | $0 | — | — | −$5.9M | −$5.3M | — | -1.22 | −$4.6M | $0 | −$4.6M | Apr 15 |
| Q3 2023 · Sep 30 | $0 | — | — | −$6.1M | −$6.1M | — | -1.39 | −$4.4M | $16K | −$4.4M | Nov 13 |
By fiscal year
| Year | Revenue | Gross margin | Operating income | Net income | Net margin | EPS | Op. cash flow | Capex | Free cash flow | Buybacks | Dividends paid |
|---|---|---|---|---|---|---|---|---|---|---|---|
| FY2025 · to Dec 31 | — | — | −$7M | −$10.3M | — | -2.00 | −$7M | — | — | — | — |
| FY2024 · to Dec 31 | — | — | −$24.6M | −$24.3M | — | -4.98 | −$15.9M | — | — | — | — |
| FY2023 · to Dec 31 | $1.1M | — | −$23.8M | −$22.9M | -2093.2% | -5.28 | −$15.3M | $218K | −$15.5M | — | — |
| FY2022 · to Dec 31 | $3.2M | — | −$24.6M | −$21M | -658.6% | -0.10 | −$19.2M | $892K | −$20M | — | — |
| FY2021 · to Dec 31 | $33K | — | −$24.7M | −$23.3M | -70554.5% | -0.11 | −$15.2M | $260K | −$15.5M | — | — |
| FY2020 · to Dec 31 | $158K | — | −$24.2M | −$22.4M | -14177.0% | -0.12 | −$17.4M | $6K | −$17.4M | — | — |
Every number comes from Matinas BioPharma Holdings, Inc.'s own XBRL-tagged filings with the SEC, not a data vendor. Quarters marked derived are the fiscal year minus the three reported quarters, the same way every data provider computes Q4. Restated figures replace originals as later filings arrive.